SRR8613701
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_EARLY+0.480
- UV_RESPONSE_DN+0.360
- PANCREAS_BETA_CELLS+0.300
- APICAL_SURFACE+0.230
- ESTROGEN_RESPONSE_LATE+0.210
- HEDGEHOG_SIGNALING+0.140
- BILE_ACID_METABOLISM+0.120
- WNT_BETA_CATENIN_SIGNALING+0.110
- KRAS_SIGNALING_DN+0.100
- MYOGENESIS+0.100
Top 10 suppressed
- E2F_TARGETS-0.660
- G2M_CHECKPOINT-0.580
- MYC_TARGETS_V2-0.550
- MYC_TARGETS_V1-0.530
- MTORC1_SIGNALING-0.500
- OXIDATIVE_PHOSPHORYLATION-0.430
- INTERFERON_GAMMA_RESPONSE-0.420
- INTERFERON_ALPHA_RESPONSE-0.410
- TNFA_SIGNALING_VIA_NFKB-0.400
- INFLAMMATORY_RESPONSE-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613714 | — | A | 0.951 |
| 2 | TCGA-44-6148-01A-11R-1755-07 | — | cohortA1 | 0.895 |
| 3 | TCGA-56-8624-01A-11R-2403-07 | — | cohortSQ1 | 0.888 |
| 4 | SRR1396640 | GTEX | — | 0.882 |
| 5 | TCGA-55-8616-01A-11R-2403-07 | — | cohortA1 | 0.882 |
| 6 | SRR1471350 | GTEX | — | 0.881 |
| 7 | C3L-00444 | — | cohortA1 | 0.881 |
| 8 | TCGA-D8-A73X-01A-11R-A32P-07 | — | B | 0.879 |
| 9 | SRR1337909 | GTEX | — | 0.878 |
| 10 | SRR1488672 | GTEX | — | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_EARLY | 0.480 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.360 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.140 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.090 | Inavolisib | — uncovered |